The estimated Net Worth of William Pridgen is at least $9.73 Thousand dollars as of 21 August 2023. William Pridgen owns over 15,335 units of Virios Therapeutics stock worth over $9,732 and over the last 4 years William sold VIRI stock worth over $0.
Sign up
William Pridgen VIRI stock SEC Form 4 insiders trading
William has made over 11 trades of the Virios Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently William bought 15,335 units of VIRI stock worth $19,936 on 21 August 2023.
The largest trade William's ever made was buying 15,335 units of Virios Therapeutics stock on 21 August 2023 worth over $19,936. On average, William trades about 3,532 units every 65 days since 2020. As of 21 August 2023 William still owns at least 52,045 units of Virios Therapeutics stock.
You can see the complete history of William Pridgen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's William Pridgen's mailing address?
William's mailing address filed with the SEC is C/O VIRIOS THERAPEUTICS, INC., 44 MILTON AVENUE, ALPHARETTA, GA, 30009.
Insiders trading at Virios Therapeutics
Over the last 4 years, insiders at Virios Therapeutics have traded over $468 worth of Virios Therapeutics stock and bought 122,044 units worth $512,255 . The most active insiders traders include John C Thomas, Richard James Whitley, and Gregory Scott Duncan. On average, Virios Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $874. The most recent stock trade was executed by William Pridgen on 21 August 2023, trading 15,335 units of VIRI stock currently worth $19,936.
What does Virios Therapeutics do?
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
What does Virios Therapeutics's logo look like?
Complete history of William Pridgen stock trades at Virios Therapeutics
Virios Therapeutics executives and stock owners
Virios Therapeutics executives and other stock owners filed with the SEC include:
-
Greg Duncan,
Chairman & CEO -
Angela Walsh,
CFO, SVP of Fin., Corp. Sec. & Treasurer -
Ralph D. Grosswald M.P.H.,
Sr. VP of Operations -
Dr. R. Michael Gendreau,
Chief Medical Officer -
Carol Duffy Ph.D.,
Chief Scientific Advisor -
William Pridgen,
-
Gregory Scott Duncan,
CHIEF EXECUTIVE OFFICER -
Angela Walsh,
SVP OF FINANCE -
Richard James Whitley,
-
Richard Alan Burch,
-
David R Keefer,
-
Ralph Grosswald,
SVP OF OPERATIONS -
John C Thomas,
-
La Rosa Abel De,